Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
SUPN Stock Chart & Stats
$55.13
$0.29(0.76%)
At close: 4:00 PM EST
$55.13
$0.29(0.76%)
Day’s Range― - ―
52-Week Range$29.16 - $57.65
Previous CloseN/A
Volume41.90K
Average Volume (3M)772.05K
Market Cap
$3.09B
Enterprise Value$1.29B
Total Cash (Recent Filing)$522.60M
Total Debt (Recent Filing)$31.77M
Price to Earnings (P/E)48.2
Beta0.59
Next Earnings
Nov 04, 2025EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding56,073,090
10 Day Avg. Volume817,900
30 Day Avg. Volume772,048
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda7.80
Forecast
1Y Price Target
$59.20Price Target Upside7.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Market ShareOnapgo, a subcutaneous infusion for Parkinson’s disease, is expected to gain market share by providing continuous dopaminergic stimulation to reduce motor fluctuations.
Product PerformanceOnapgo's prescription growth indicates an aggressive growth trajectory, which has led to upward revisions in estimates.
Revenue GuidanceSUPN raised revenue guidance to $670-700 million, reflecting strong Qelbree performance and acquisition of Zurzuvae.
Bears Say
Commercial Uptake RisksThe primary risk to the investment thesis is slower-than-expected commercial uptake for Qelbree and Onapgo, as well as earlier than expected generic competitor launch.
Supernus Pharmaceuticals News
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $29.16 and its highest was $57.65 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $3.09B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Nov 04, 2025 which is in 2 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported $0.908 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.438.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.59.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 56,073,090 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.908 in its last earnings report, beating expectations of $0.47. Following the earnings report the stock price went up 13.083%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in SUPN
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.20 (7.38% Upside)
$59.20 (7.38% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 782.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.81%
12-Months-Change
Fundamentals
Return on Equity
6.38%
Trailing 12-Months
Asset Growth
5.06%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for the treatment of central nervous system (CNS) diseases. The company primarily operates in the pharmaceutical sector, specializing in therapies for epilepsy, depression, and attention deficit hyperactivity disorder (ADHD). Supernus's core products include several FDA-approved medications such as Oxtellar XR and Trokendi XR, which are designed to address the needs of patients suffering from these conditions.
SUPN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Supernus Pharmaceuticals reported a strong Q2 2025 with significant achievements such as the launch of ONAPGO, acquisition of Sage Therapeutics, and robust growth in key products like Qelbree and GOCOVRI. However, challenges remain with declines in legacy product sales, increased operating expenses, and a projected operating loss for 2025. Overall, the positive developments and future growth potential outweigh the negatives.View all SUPN earnings summariesSUPN Stock 12 Month Forecast
Average Price Target
$59.20
▲(7.38% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Perrigo Company
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Alvotech
―
Ownership Overview
4.36% Insiders
34.25% Mutual Funds
1.05% Other Institutional Investors
32.73% Public Companies and
Individual Investors